SCHEMBL5066142

SCHEMBL5066142

CCCCCCCCC=CCCCCCCCCCCCCCC(=O)ON1C(=O)CCC1=O

nearest known ligand 0.49

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PRKCA P17252 2/20 0.49
FAAH O00519 5/20 0.49
TERT O14746 3/20 0.49
PTPN1 P18031 3/20 0.49
PPARG P37231 3/20 0.49
PPARD Q03181 3/20 0.49
PPARA Q07869 3/20 0.49
CYP1A2 P05177 2/20 0.49
MAPT P10636 2/20 0.49
CYP2C19 P33261 2/20 0.49
BLM P54132 2/20 0.49
HSD17B10 Q99714 2/20 0.49
FABP4 P15090 2/20 0.49
KMT2A Q03164 2/20 0.49
GMNN O75496 1/20 0.49
USP2 O75604 1/20 0.49
LMNA P02545 1/20 0.49
POLB P06746 1/20 0.49
CYP2C9 P11712 1/20 0.49
ALOX15 P16050 1/20 0.49

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2779347 1.00 PRKCA (0.49) PRKCAFAAHTERTPTPN1PPARG
SCHEMBL5066137 1.00 PRKCA (0.49) PRKCAFAAHTERTPTPN1PPARG
SCHEMBL17780094 1.00 PRKCA (0.49) PRKCAFAAHTERTPTPN1PPARG
SCHEMBL2779350 1.00 PRKCA (0.49) PRKCAFAAHTERTPTPN1PPARG
SCHEMBL18206407 1.00 PRKCA (0.49) PRKCAFAAHTERTPTPN1PPARG
SCHEMBL12435787 0.96 MGLL (0.55) FAAHPPARGPPARDPPARAHSD17B10
SCHEMBL23417025 0.92 FAAH (0.56) FAAHPPARGPPARDPPARAMAPT
SCHEMBL27409126 0.91 MGLL (0.43) PRKCAFAAHMAPTKMT2APGR
SCHEMBL1361856 0.91 KMT2A (0.54) PRKCAKMT2ALMNA
SCHEMBL18218758 0.91 KMT2A (0.54) PRKCAKMT2ALMNA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1914223-A1 Anti-inflammatory and immunomodulatory amino acid derivatives, their preparation and use CRODA INTERNATIONAL plc (GB) 2008-04-23 EP disclosed
US-6956059-B2 Anti-inflammatory and immunomodulatory amino acid derivatives, their preparation and use CRODA INTERNATIONAL, PLC (GB) 2005-10-18 US disclosed
US-20040242663-A1 Anti-inflammatory and immunomodulatory amino acid derivatives, their preparation and use CRODA INTERNATIONAL, PLC (GB) 2004-12-02 US disclosed
EP-1389180-A1 ANTI-INFLAMMATORY AND IMMUNOMODULATORY AMINO ACID DERIVATIVES, THEIR PREPARATION AND USE CRODA INTERNATIONAL plc (GB) 2004-02-18 EP disclosed
WO-2002094764-A1 ANTI-INFLAMMATORY AND IMMUNOMODULATORY AMINO ACID DERIVATIVES, THEIR PREPARATION AND USE CRODA INTERNATIONAL PLC (GB) 2002-11-28 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040242663-A1 Anti-inflammatory and immunomodulatory amino acid derivatives, their preparation and use ARG1, IL6, IL4I1 PRKCA 1995/4885FAAH 428/4885TERT 4808/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.